What question did this study set out to answer?

Investigate the incidence of impaired graft function post-HSCT for myelofibrosis and the role of stem cell boosts.

December 8, 2025BloodOpen Access

High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis highlights impaired graft function rates in myelofibrosis after HSCT, suggesting potential benefits from stem cell boosts.

Investigate the incidence of impaired graft function post-HSCT for myelofibrosis and the role of stem cell boosts.
Retrospective analysis of 50 myelofibrosis patients post-HSCT
Defined primary graft failure and prolonged poor graft function
Survival outcomes censored at 2 years to minimize time bias.
8 patients (16%) met criteria for primary graft failure
5 additional patients (10%) experienced prolonged poor graft function
Overall survival at 2 years was 40% for primary graft failure group and 75% for prolonged poor graft function group.

Philips et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis highlights impaired graft function rates in myelofibrosis after HSCT, suggesting potential benefits from stem cell boosts.